Results 31 to 40 of about 492 (136)

Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess [PDF]

Frontiers in Pharmacology
BackgroundPulmonary fibrosis is a severe and potentially fatal adverse event, and its association with disease-modifying antirheumatic drugs (DMARDs) has raised long-standing concerns. However, systematic investigations on this topic are lacking.
Xinyue Zhang, Xinhui Wu, Cheng Luo, Chun Yang, Nan Jia, Jiayi He, Qian Chen, Fei Wang   +7 more
doaj   +2 more sources

Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases [PDF]

Frontiers in Pharmacology
BackgroundCaspofungin, micafungin, and anidulafungin are three commonly used echinocandins recommended for the treatment of invasive candidiasis. This study aimed to comprehensively evaluate the safety profiles of these three agents to assist clinicians ...
Jingxiu Chen, Chunhua Chen, Xiaobin Lin, Jiajia Yan, Yifan Zheng, Yifan Zheng, Pan Chen, Jia Li, Jia Li   +8 more
doaj   +2 more sources

Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study [PDF]

Frontiers in Medicine
BackgroundLeukotriene receptor antagonists (LTRAs), including montelukast, pranlukast, and zafirlukast, are generally well tolerated and widely used for asthma and allergic rhinitis, but they may cause adverse drug reactions (ADRs).
Youlin Dong, Zhigang Xia, Weimin Gao
doaj   +2 more sources

VigiAccess Covid-19 dataset

Background: The monitoring and analysis of adverse drug reactions (ADR’s) play a pivotal role in ensuring drug safety. In the context of a public health emergency of international concern (PHEIC), and the roll out of experimental COVID-19 vaccines, the need for a comprehensive database and process to scrutinize ADRs is imperative.Areas of uncertainty ...
Andrew Bryant, Theresa Lawrie
openaire   +2 more sources

Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases. [PDF]

PLoS ONE
BackgroundVutrisiran is a double-stranded siRNA targeting transthyretin mRNA, primarily for the treatment of transthyretin-mediated amyloidosis (ATTR) with polyneuropathy.
Weiwei Tong, Yaxing Li, Xingli Xu, Yang Mao, Ruonan Zhang, Chuanliang Zhao, Jidang Zhang, Chigang Du, Jiayue Feng   +8 more
doaj   +2 more sources

Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess [PDF]

Frontiers in Pharmacology
PurposeBreast cancer is the most common malignancy in women. Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients rely on endocrine therapy as their fundamental systemic treatment strategy.
Guoqiang Li, Mengqi Yang, Lei Zhang, Xin Li, Xiaoliang Wu, Feng Peng, Yajie Liu   +6 more
doaj   +2 more sources

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Case Reports in Nephrology, 2020
Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the
Gisela Marcelino, Ould Maouloud Hemett, Eric Descombes   +2 more
doaj   +2 more sources

A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration’s adverse event reporting system databases [PDF]

Frontiers in Immunology
ObjectiveThe study bridge statistical pharmacovigilance signals to clinically actionable insights by systematically characterizing adverse event (AE) patterns associated with ublituximab and identifying previously unrecognized risks.
Jiagnang Cao, Qinguo Shen, Yan Zou
doaj   +2 more sources

DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionDNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders.
Qiang Zhou, Quanlei Xie, Qiang Liu, Haojie Wang, Zhan Zhang, Zhao Yu, Qian Guo, Jie Lin   +7 more
doaj   +3 more sources

Safety profile of ticagrelor: an analysis based on literature and database review [PDF]

BMC Cardiovascular Disorders
Objective Ticagrelor, a reversible P2Y12 receptor antagonist, is widely used in acute coronary syndromes (ACS) for its superior efficacy over clopidogrel.
Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu   +3 more
doaj   +2 more sources